Mazhar Hussain
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Mazhar Hussain has a total of 39 co-authors. Here are the top co-authors by number of shared publications:
Lubna Akhtar
Hosp Rahim Yar Khan, Dept Pharmacol & Therapeut, Sheikh Zayed Med Coll, Rahim Yar Khan, Punjab, Pakistan
11 shared publicationsJaved Iqbal
Department of Medicine, Sheikh Zayed MedicalCollege and Hospital, Rahim Yar Khan, Punjab, Pakistan
6 shared publicationsMoazzam Ali Atif
Department of Pharmacology, Sheikh Zayed Medical College, Rahim Yar Khan, Pakistan
4 shared publicationsAkbar Waheed
Departmentof Pharmacology, Riphah International University, Islamabad, Pakistan
3 shared publicationsAsim Elahi
Department of Internal Medicine,South Texas Health System McAllen, Texas, 78503, United States
3 shared publicationsMuhammad Bilal Ghafoor
Pathology, Sheikh Zayed Medical College and Hospital, Rahim Yar Khan, PAK
3 shared publications
Latest Publications
- Open Access
- 1 February 2026
- Published by Bentham Science Publishers Ltd. in Current Diabetes Reviews
- Vol. 22 (2) , 1-9
FTO Gene rs9939609 is Potentially Associated with Diabetes Related Complications in T2DM Patients
Introduction: FTO gene rs9939609, an obesity susceptible gene, has strong with type 2 diabetes mellitus (T2DM). Studies have also established an association between the FTO gene rs9939609 and cardiovascular disease (CVD). This research investigated the association of this genetic variant with microvascular and macrovascular complications related to diabetes. Materials and Methods: We performed a cross-sectional analysis involving 140 participants with T2DM and 70 healthy control subjects. The DNA samples were analyzed for the FTO gene variant rs9939609 using ARMS-PCR. FTO gene association with diabetes-related microvascular and macrovascular complications was assessed through multivariate logistic regression, with unadjusted odds ratios (OR) and 95% confidence intervals. A p- value below 0.05 was considered statistically significant. Results and Discussion: The genotypic distribution of the FTO gene variant adhered to Hardy-Weinberg equilibrium in the study participants (p>0.05).The AA genotype exhibited a robust association with elevated BMI, HbA1C, SBP, DBP, TGs and decreased HDL-C levels relative to the AT and TT genotypes with p=0.002. FTO genotype frequency increased from AA to AT to TT in both macrovascular (CVD) and microvascular complications (retinopathy, nephropathy, and neuropathy). Moreover, risk allele(A) was also significantly contributed to CVD (p=0.001), retinopathy (p=0.004), nephropathy (p=0.001) and neuropathy (p=0.002). AA genotype of the FTO gene rs 9939609 showed the tendency to increase the risk of CVD (OR,1.21; 95% CI,1.07-1.70; p=0.04) and retinopathy (OR,1.18; 95%CI,1.02-1.87;; p=0.001) while no significant changes were recorded in diabetic nephropathy (OR,1.56; 95%CI,1.2-2.43; p=0.67) and neuropathy (OR,2.49; 95%,1.52-4.1; p=0.06). Conclusion: Our data indicate that the FTO gene variant rs 9939609 is linked to an elevated risk of both microvascular & macrovascular complications in individuals with T2DM.
- 1 February 2026
- Published by Bentham Science Publishers Ltd. in Current Diabetes Reviews
- Vol. 22 (2) , 1-9
Open AccessFTO Gene rs9939609 is Potentially Associated with Diabetes Related Complications in T2DM Patients
Introduction: FTO gene rs9939609, an obesity susceptible gene, has strong with type 2 diabetes mellitus (T2DM). Studies have also established an association between the FTO gene rs9939609 and cardiovascular disease (CVD). This research investigated the association of this genetic variant with microvascular and macrovascular complications related to diabetes. Materials and Methods: We performed a cross-sectional analysis involving 140 participants with T2DM and 70 healthy control subjects. The DNA samples were analyzed for the FTO gene variant rs9939609 using ARMS-PCR. FTO gene association with diabetes-related microvascular and macrovascular complications was assessed through multivariate logistic regression, with unadjusted odds ratios (OR) and 95% confidence intervals. A p- value below 0.05 was considered statistically significant. Results and Discussion: The genotypic distribution of the FTO gene variant adhered to Hardy-Weinberg equilibrium in the study participants (p>0.05).The AA genotype exhibited a robust association with elevated BMI, HbA1C, SBP, DBP, TGs and decreased HDL-C levels relative to the AT and TT genotypes with p=0.002. FTO genotype frequency increased from AA to AT to TT in both macrovascular (CVD) and microvascular complications (retinopathy, nephropathy, and neuropathy). Moreover, risk allele(A) was also significantly contributed to CVD (p=0.001), retinopathy (p=0.004), nephropathy (p=0.001) and neuropathy (p=0.002). AA genotype of the FTO gene rs 9939609 showed the tendency to increase the risk of CVD (OR,1.21; 95% CI,1.07-1.70; p=0.04) and retinopathy (OR,1.18; 95%CI,1.02-1.87;; p=0.001) while no significant changes were recorded in diabetic nephropathy (OR,1.56; 95%CI,1.2-2.43; p=0.67) and neuropathy (OR,2.49; 95%,1.52-4.1; p=0.06). Conclusion: Our data indicate that the FTO gene variant rs 9939609 is linked to an elevated risk of both microvascular & macrovascular complications in individuals with T2DM.
- Open Access
- 30 July 2025
- Published by Independent Medical Trust in The Professional Medical Journal
- Vol. 32 (08) , 940-948
To compare the efficacy and safety profile of empagliflozin and sitagliptin as an add on therapy to metformin in T2DM patients.
Objective: To compare the efficacy and safety and profile of empagliflozin and sitagliptin as an add on therapy to metformin in T2DM patients. Study Design: Randomized Controlled Trial. Period: January to March 2024. Setting: Sheikh Zayed Medical College & Hospital, Rahim Yar Khan. Methods: A total of 280 T2DM patients with inadequate glycemic control on metformin were randomly assigned to receive either empagliflozin or sitagliptin. The primary outcomes included changes in body weight (BW), body mass index (BMI), fasting blood glucose (FBG), HbA1c, systolic and diastolic blood pressure (SBP, DBP), and lipid profile. Secondary outcomes involved monitoring adverse effects throughout the study. Results: After 12 weeks, both groups showed significant reductions in BW and BMI, with empagliflozin showing greater improvements (BW: 92.5±13.5 to 79±14.5 kg, BMI: 29.4±4.2 to 27.5±3.8) compared to sitagliptin (BW: 89±16.6 to 81±12.5 kg, BMI: 28.5±5.6 to 27.3±4.2). Similarly, empagliflozin more effectively reduced FBG (240±60.5 to 130±35.5 mg/dL) and HbA1c (8.35±1.9% to 7.2±1.6%) compared to sitagliptin. Both drugs were well-tolerated with no major adverse effects. Conclusion: Empagliflozin demonstrated superior efficacy and safety compared to sitagliptin as an add-on therapy to metformin in T2DM management.
- 30 July 2025
- Published by Independent Medical Trust in The Professional Medical Journal
- Vol. 32 (08) , 940-948
Open AccessTo compare the efficacy and safety profile of empagliflozin and sitagliptin as an add on therapy to metformin in T2DM patients.
Objective: To compare the efficacy and safety and profile of empagliflozin and sitagliptin as an add on therapy to metformin in T2DM patients. Study Design: Randomized Controlled Trial. Period: January to March 2024. Setting: Sheikh Zayed Medical College & Hospital, Rahim Yar Khan. Methods: A total of 280 T2DM patients with inadequate glycemic control on metformin were randomly assigned to receive either empagliflozin or sitagliptin. The primary outcomes included changes in body weight (BW), body mass index (BMI), fasting blood glucose (FBG), HbA1c, systolic and diastolic blood pressure (SBP, DBP), and lipid profile. Secondary outcomes involved monitoring adverse effects throughout the study. Results: After 12 weeks, both groups showed significant reductions in BW and BMI, with empagliflozin showing greater improvements (BW: 92.5±13.5 to 79±14.5 kg, BMI: 29.4±4.2 to 27.5±3.8) compared to sitagliptin (BW: 89±16.6 to 81±12.5 kg, BMI: 28.5±5.6 to 27.3±4.2). Similarly, empagliflozin more effectively reduced FBG (240±60.5 to 130±35.5 mg/dL) and HbA1c (8.35±1.9% to 7.2±1.6%) compared to sitagliptin. Both drugs were well-tolerated with no major adverse effects. Conclusion: Empagliflozin demonstrated superior efficacy and safety compared to sitagliptin as an add-on therapy to metformin in T2DM management.
- Open Access
- 1 January 2024
- Published by Wiley in Journal of Diabetes Research
- Vol. 2024 (1) , 5914316
Fat Mass and Obesity‐Related (FTO) Gene Variant Is a Predictor of CVD in T2DM Patients
Background: The role of the common FTO gene variant rs9939609 in obesity has been well established, and the FTO gene has a strong association with T2DM.Objective: To investigate the association of FTO gene variant rs9939609 with obesity‐related parameters in T2DM and CVD patients.Materials and Methods: In this cross‐sectional study, 280 subjects of either sex aged 45.10 ± 9.6 years were randomly divided into four groups, that is, T2DM, T2DM with CVD, nondiabetic with CVD disease, and normal control. These samples were genotyped by ARMS‐PCR. The FTO gene association with obesity‐related parameters in T2DM and CVD patients was analyzed by SPSS 22.Results: The TT genotype was the most common genotype (46.80%) in our study groups. The minor allele frequency (MAF) was significantly higher in T2DM patients (0.39 vs. 0.28), T2DM patients with CVD (0.43 vs. 0.28), and nondiabetic patients with CVD (0.35 vs. 0.28) as compared to control with p < 0.005. Carriers of the AA genotype of the FTO gene rs9939609 were significantly associated with increased BMI, WC, HbA1C, SBP, DBP, and TGs and lowered HDL cholesterol as compared to the TA and TT genotypes in T2DM and CVD patients with p < 0.005. The FTO gene variant rs9939609 showed a significant association with T2DM and CVD. The AA genotype odds ratio (OR) in T2DM was 1.48 (1.06–2.32), p = 0.006, and in CVD, it was 1.56 (1.04–2.4), p = 0.003.Conclusion: The FTO gene variant rs9939609 has a strong association with T2DM and CVD. The AA genotype of FTO gene variants rs9939609 showed a strong association with most of the risk factors of CVD and T2DM.
- 1 January 2024
- Published by Wiley in Journal of Diabetes Research
- Vol. 2024 (1) , 5914316
Open AccessFat Mass and Obesity‐Related (FTO) Gene Variant Is a Predictor of CVD in T2DM Patients
Background: The role of the common FTO gene variant rs9939609 in obesity has been well established, and the FTO gene has a strong association with T2DM.Objective: To investigate the association of FTO gene variant rs9939609 with obesity‐related parameters in T2DM and CVD patients.Materials and Methods: In this cross‐sectional study, 280 subjects of either sex aged 45.10 ± 9.6 years were randomly divided into four groups, that is, T2DM, T2DM with CVD, nondiabetic with CVD disease, and normal control. These samples were genotyped by ARMS‐PCR. The FTO gene association with obesity‐related parameters in T2DM and CVD patients was analyzed by SPSS 22.Results: The TT genotype was the most common genotype (46.80%) in our study groups. The minor allele frequency (MAF) was significantly higher in T2DM patients (0.39 vs. 0.28), T2DM patients with CVD (0.43 vs. 0.28), and nondiabetic patients with CVD (0.35 vs. 0.28) as compared to control with p < 0.005. Carriers of the AA genotype of the FTO gene rs9939609 were significantly associated with increased BMI, WC, HbA1C, SBP, DBP, and TGs and lowered HDL cholesterol as compared to the TA and TT genotypes in T2DM and CVD patients with p < 0.005. The FTO gene variant rs9939609 showed a significant association with T2DM and CVD. The AA genotype odds ratio (OR) in T2DM was 1.48 (1.06–2.32), p = 0.006, and in CVD, it was 1.56 (1.04–2.4), p = 0.003.Conclusion: The FTO gene variant rs9939609 has a strong association with T2DM and CVD. The AA genotype of FTO gene variants rs9939609 showed a strong association with most of the risk factors of CVD and T2DM.
- 1 September 2021
- Published by Faculty of Pharmacy and Pharmaceutical Sciences, University of Karachi
- Vol. 34 (5) , 1891-1895
Effect of nebivolol beneficial on lipid profile and glycemic control in comparison with Atenolol in patients with type 2 DM with concomitant hypertension
Blood pressure control in hypertensive patients with metabolic abnormalities is challenging because many antihypertensive drugs adversely affect metabolism. Nebivolol a 3rd generation vasodilatory beta-blocker offer neutral or beneficial effects on insulin sensitivity and lipid metabolism. The purpose of this study was to evaluate the effect of nebivolol and atenolol on glycemic control and lipid profile in type 2 diabetes patients with concomitant hypertension. We conducted a 12 weeks double blind randomized clinical trial at Sheik Zayed Hospital Rahim Yar Khan. Patients were randomly divided in to two groups. Patients in group were given tablet nebivolol 5-10mg while patients in group B were given tablet Atenolol 25-50mg/daily for a period of 12 weeks. Pre and post data were analyzed by SPSS 20. After 12 weeks, Both drugs lowered blood pressure significantly i.e. nebivolol (SBP from152 +/- 12 to130 +/- 14 with p=0.004, DBP from 95 +/- 12 to78 +/- 8.5 with p=0.002) Atenolol (SBP from148 +/- 16.5 to 128 +/- 15.5 with p=0.006, DBP from 90 +/- 10.5 to 82 +/- 12 with p=0.003).Similarly both Nebivolol and Atenolol did not any significant effect on glycemic control and lipid profile at 12 week with in groups. However when comparison was done between two groups, Nebivolol significantly reduced blood sugar (p=0.001), HbA1c (p=0.0032), total Cholesterol (p=0.002), triglycerides (p=0.012), LDLCholesterol (p=0.007) and HDL-Cholesterol (p=0.001) as compared to atenolol. In comparison with atenolol, Nebivolol has a beneficial effect on glycemic control and serum lipid profile.
- 1 September 2021
- Published by Faculty of Pharmacy and Pharmaceutical Sciences, University of Karachi
- Vol. 34 (5) , 1891-1895
Effect of nebivolol beneficial on lipid profile and glycemic control in comparison with Atenolol in patients with type 2 DM with concomitant hypertension
Blood pressure control in hypertensive patients with metabolic abnormalities is challenging because many antihypertensive drugs adversely affect metabolism. Nebivolol a 3rd generation vasodilatory beta-blocker offer neutral or beneficial effects on insulin sensitivity and lipid metabolism. The purpose of this study was to evaluate the effect of nebivolol and atenolol on glycemic control and lipid profile in type 2 diabetes patients with concomitant hypertension. We conducted a 12 weeks double blind randomized clinical trial at Sheik Zayed Hospital Rahim Yar Khan. Patients were randomly divided in to two groups. Patients in group were given tablet nebivolol 5-10mg while patients in group B were given tablet Atenolol 25-50mg/daily for a period of 12 weeks. Pre and post data were analyzed by SPSS 20. After 12 weeks, Both drugs lowered blood pressure significantly i.e. nebivolol (SBP from152 +/- 12 to130 +/- 14 with p=0.004, DBP from 95 +/- 12 to78 +/- 8.5 with p=0.002) Atenolol (SBP from148 +/- 16.5 to 128 +/- 15.5 with p=0.006, DBP from 90 +/- 10.5 to 82 +/- 12 with p=0.003).Similarly both Nebivolol and Atenolol did not any significant effect on glycemic control and lipid profile at 12 week with in groups. However when comparison was done between two groups, Nebivolol significantly reduced blood sugar (p=0.001), HbA1c (p=0.0032), total Cholesterol (p=0.002), triglycerides (p=0.012), LDLCholesterol (p=0.007) and HDL-Cholesterol (p=0.001) as compared to atenolol. In comparison with atenolol, Nebivolol has a beneficial effect on glycemic control and serum lipid profile.
- 23 July 2021
- Published by Springer Nature in International Journal of Diabetes in Developing Countries
- Vol. 42 (2) , 290-296
Therapeutic outcome of dapagliflozin on various parameters in non-alcoholic fatty liver disease (NAFLD) patients
- 23 July 2021
- Published by Springer Nature in International Journal of Diabetes in Developing Countries
- Vol. 42 (2) , 290-296
Therapeutic outcome of dapagliflozin on various parameters in non-alcoholic fatty liver disease (NAFLD) patients
- Open Access
- 1 July 2021
- Published by Khyber Medical University in Khyber Medical University Journal
- Vol. 13 (3) , 152-156
IMPACT OF ANTIBIOTIC STEWARDSHIP LEARNING SESSION ON KNOWLEDGE AND ATTITUDE OF UNDERGRADUATE MEDICAL STUDENTS
OBJECTIVE: To investigate the impact of antibiotic stewardship session on knowledge and attitude of 3 year medical and allied health sciences students of rd Sheikh Zayed Medical College (SZMC) Rahim Yar Khan, Pakistan. METHODS: This cross-sectional study was conducted on 3 year rd undergraduate medical students of SZMC Rahim Yar Khan, Pakistan. Knowledge of antibiotic stewardship was given to them through lectures, tutorials and small group discussion from May 2019 to December 2020. A structured proforma with questionnaires about antibiotic stewardship was given to them to fill in before and after the learning session. RESULTS: Out of 585, 500 students completed the proforma before and after the antibiotic stewardship session and the response rate was 85%. Although more than 80% of the students had significant knowledge pre-and post antibiotic stewardship session but only 6% of students were familiar with term antibiotic stewardship pre-session as compared to 93% post-session (p <0.005). After the learning session more than 85% of students significantly agreed that antibiotic stewardship improve patient care, reduce bacterial resistance, decrease hospital stay and cost (p <0.005). Similarly, after session there was significant improvement regarding collaborative approaches for the appropriate use of antibiotics, work with inter professional team, role of each profession for appropriate use of antibiotics, collaboration with microbiologist and pharmacist (p<0.005). There was significant improvement to use broad and narrow spectrum antibiotics on the basis of definite and provisional diagnosis after session (p <0.005). CONCLUSION: Antibiotic stewardship session has positive impact on knowledge and attitude of undergraduate medical students.
- 1 July 2021
- Published by Khyber Medical University in Khyber Medical University Journal
- Vol. 13 (3) , 152-156
Open AccessIMPACT OF ANTIBIOTIC STEWARDSHIP LEARNING SESSION ON KNOWLEDGE AND ATTITUDE OF UNDERGRADUATE MEDICAL STUDENTS
OBJECTIVE: To investigate the impact of antibiotic stewardship session on knowledge and attitude of 3 year medical and allied health sciences students of rd Sheikh Zayed Medical College (SZMC) Rahim Yar Khan, Pakistan. METHODS: This cross-sectional study was conducted on 3 year rd undergraduate medical students of SZMC Rahim Yar Khan, Pakistan. Knowledge of antibiotic stewardship was given to them through lectures, tutorials and small group discussion from May 2019 to December 2020. A structured proforma with questionnaires about antibiotic stewardship was given to them to fill in before and after the learning session. RESULTS: Out of 585, 500 students completed the proforma before and after the antibiotic stewardship session and the response rate was 85%. Although more than 80% of the students had significant knowledge pre-and post antibiotic stewardship session but only 6% of students were familiar with term antibiotic stewardship pre-session as compared to 93% post-session (p <0.005). After the learning session more than 85% of students significantly agreed that antibiotic stewardship improve patient care, reduce bacterial resistance, decrease hospital stay and cost (p <0.005). Similarly, after session there was significant improvement regarding collaborative approaches for the appropriate use of antibiotics, work with inter professional team, role of each profession for appropriate use of antibiotics, collaboration with microbiologist and pharmacist (p<0.005). There was significant improvement to use broad and narrow spectrum antibiotics on the basis of definite and provisional diagnosis after session (p <0.005). CONCLUSION: Antibiotic stewardship session has positive impact on knowledge and attitude of undergraduate medical students.
- Open Access
- 17 June 2021
- Published by Hindawi Limited in Journal of Diabetes Research
- Vol. 2021, 1-5
Sodium-Glucose Cotransporter-2 (SGLT-2) Attenuates Serum Uric Acid (SUA) Level in Patients with Type 2 Diabetes
Background. Hyperuricemia has a strong association with diabetes mellitus. Hyperuricemia can lead to cardiovascular and renal complications in patients with diabetes. The goal of this study was to compare the effect of sodium-glucose cotransporter-2 (SGLT-2) inhibitors dapagliflozin and empagliflozin on serum uric acid (SUA) levels in patients with type 2 diabetes against traditional oral antihyperglycemic drugs (OADs). Methods. In this double-blind randomized controlled trial, 70 patients with type 2 diabetes and elevated SUA levels were assigned to two treatment groups. Patients in group A received SGLT-2 inhibitors tablet dapagliflozin 5 mg to 10 mg and empagliflozin 10 mg to 25 mg. Group B patients received OADs such as glimepiride, metformin, sitagliptin, gliclazide, and glibenclamide as monotherapy or combination therapy. The changes in SUA level were primary end points while changes in body weight and body mass index (BMI) from baseline to end point were secondary end points. Results. After four weeks of treatment, we noted a significant reduction of mean SUA levels in the SGLT-2 inhibitor group fromto mg/dl versus comparator group fromto mg/dl (). Mean body weight was significantly reduced in the SGLT-2 group fromto kg versus comparator group fromto kg (). Similarly, the mean BMI of patients in the SGLT-2 group was significantly reduced fromto kg/m2 versus comparator group fromto kg/m2 (). Conclusion. SGLT-2 inhibitors have a strong potential to decrease SUA levels in patients with type 2 diabetes.- 17 June 2021
- Published by Hindawi Limited in Journal of Diabetes Research
- Vol. 2021, 1-5
Open AccessSodium-Glucose Cotransporter-2 (SGLT-2) Attenuates Serum Uric Acid (SUA) Level in Patients with Type 2 Diabetes
Background. Hyperuricemia has a strong association with diabetes mellitus. Hyperuricemia can lead to cardiovascular and renal complications in patients with diabetes. The goal of this study was to compare the effect of sodium-glucose cotransporter-2 (SGLT-2) inhibitors dapagliflozin and empagliflozin on serum uric acid (SUA) levels in patients with type 2 diabetes against traditional oral antihyperglycemic drugs (OADs). Methods. In this double-blind randomized controlled trial, 70 patients with type 2 diabetes and elevated SUA levels were assigned to two treatment groups. Patients in group A received SGLT-2 inhibitors tablet dapagliflozin 5 mg to 10 mg and empagliflozin 10 mg to 25 mg. Group B patients received OADs such as glimepiride, metformin, sitagliptin, gliclazide, and glibenclamide as monotherapy or combination therapy. The changes in SUA level were primary end points while changes in body weight and body mass index (BMI) from baseline to end point were secondary end points. Results. After four weeks of treatment, we noted a significant reduction of mean SUA levels in the SGLT-2 inhibitor group fromto mg/dl versus comparator group fromto mg/dl (). Mean body weight was significantly reduced in the SGLT-2 group fromto kg versus comparator group fromto kg (). Similarly, the mean BMI of patients in the SGLT-2 group was significantly reduced fromto kg/m2 versus comparator group fromto kg/m2 (). Conclusion. SGLT-2 inhibitors have a strong potential to decrease SUA levels in patients with type 2 diabetes. - Open Access
- 3 April 2021
- Published by Springer Nature in Cureus
- Vol. 13 (4)
Comparison of Efficacy and Safety Profile of Sodium-Glucose Cotransporter-2 Inhibitors as Add-On Therapy in Patients With Type 2 Diabetes
Background Type 2 diabetes is a chronic metabolic disorder that is escalating at an alarming rate worldwide. Sodium-glucose cotransporter-2 (SGLT-2) inhibitors are recent oral antihyperglycemic drugs (OADs) with a unique mechanism of action. Objectives This study aimed compared the efficacy and safety profiles of two SGLT-2 inhibitors, empagliflozin and dapagliflozin, in patients with type 2 diabetes as add-on therapy to traditional first-line OADs. Methods We conducted a randomized controlled trial comparing empagliflozin and dapagliflozin in patients with type 2 diabetes. Patients were included in the study if they had type 2 diabetes with inadequate glycemic control, defined as glycated hemoglobin (HbA1c) of 7.5% to 11.0%, treated with conventional first-line OADs. Study participants were randomly assigned into two groups. Group A patients received oral empagliflozin, 10 to 25 mg, and Group B patients received oral dapagliflozin, 5 to 10 mg, for 12 weeks. The primary endpoint was the efficacy profile for each SGLT-2 agent in terms of body weight changes, body mass index (BMI), fasting blood glucose (FBG), and HbA1c. The secondary endpoint was to determine the safety and tolerability profiles of each SGLT-2 agent. Results After 12 weeks of treatment, the mean body weight was reduced significantly in both groups from baseline (empagliflozin: -3.2 kg ± 5.5 kg, p = 0.003; dapagliflozin -2.1 kg ± 4.6 kg, p = 0.008). However, the mean body weight reduction between groups was not statistically significant (p = 0.078). BMI was significantly reduced in both groups (empagliflozin from 28.5 ± 4.9 kg/m2 to 25.8 ± 5.2 kg/m2, p = 0.002; dapagliflozin from 29 ± 5.2 kg/m2 to 27.7 ± 4.8 kg/m2, p = 0.003). However, the patients who received empagliflozin experienced a significantly greater reduction in BMI than patients who received dapagliflozin (p = 0.007). The mean FBG was also reduced in both study groups (empagliflozin: -88.5 mg/dL ± 39.7 mg/dl, p = 0.003; dapagliflozin: -59.8 mg/dL ± 48.5 mg/dL; p = 0.007). However, the patients who received empagliflozin experienced a significantly greater reduction in mean FBG than patients who received dapagliflozin (p = 0.001). HbA1c was also significantly reduced in both groups (empagliflozin: -2.1% ± 1.1%, p = 0.002; dapagliflozin: -1.4% ± 0.9%; p = 0.004). However, patients who received empagliflozin experienced a significantly greater reduction in HbA1c than patients who received dapagliflozin (p = 0.001). The tolerability profiles of both SGLT-2 agents were quite good, and no major adverse effects were reported in the study groups. Urinary infection occurred more often in patients who received dapagliflozin (9.3%) than in patients who received empagliflozin (4.5%; p = 0.002). Patients in the dapagliflozin group also had a higher incidence of genital infections (7.3%) than those in the empagliflozin group (3.8%; p = 0.001). Conclusion Both empagliflozin and dapagliflozin demonstrated excellent efficacy and safety profiles in our study. These agents should be considered as add-on therapy in patients with type 2 diabetes taking conventional first-line OADs.
- 3 April 2021
- Published by Springer Nature in Cureus
- Vol. 13 (4)
Open AccessComparison of Efficacy and Safety Profile of Sodium-Glucose Cotransporter-2 Inhibitors as Add-On Therapy in Patients With Type 2 Diabetes
Background Type 2 diabetes is a chronic metabolic disorder that is escalating at an alarming rate worldwide. Sodium-glucose cotransporter-2 (SGLT-2) inhibitors are recent oral antihyperglycemic drugs (OADs) with a unique mechanism of action. Objectives This study aimed compared the efficacy and safety profiles of two SGLT-2 inhibitors, empagliflozin and dapagliflozin, in patients with type 2 diabetes as add-on therapy to traditional first-line OADs. Methods We conducted a randomized controlled trial comparing empagliflozin and dapagliflozin in patients with type 2 diabetes. Patients were included in the study if they had type 2 diabetes with inadequate glycemic control, defined as glycated hemoglobin (HbA1c) of 7.5% to 11.0%, treated with conventional first-line OADs. Study participants were randomly assigned into two groups. Group A patients received oral empagliflozin, 10 to 25 mg, and Group B patients received oral dapagliflozin, 5 to 10 mg, for 12 weeks. The primary endpoint was the efficacy profile for each SGLT-2 agent in terms of body weight changes, body mass index (BMI), fasting blood glucose (FBG), and HbA1c. The secondary endpoint was to determine the safety and tolerability profiles of each SGLT-2 agent. Results After 12 weeks of treatment, the mean body weight was reduced significantly in both groups from baseline (empagliflozin: -3.2 kg ± 5.5 kg, p = 0.003; dapagliflozin -2.1 kg ± 4.6 kg, p = 0.008). However, the mean body weight reduction between groups was not statistically significant (p = 0.078). BMI was significantly reduced in both groups (empagliflozin from 28.5 ± 4.9 kg/m2 to 25.8 ± 5.2 kg/m2, p = 0.002; dapagliflozin from 29 ± 5.2 kg/m2 to 27.7 ± 4.8 kg/m2, p = 0.003). However, the patients who received empagliflozin experienced a significantly greater reduction in BMI than patients who received dapagliflozin (p = 0.007). The mean FBG was also reduced in both study groups (empagliflozin: -88.5 mg/dL ± 39.7 mg/dl, p = 0.003; dapagliflozin: -59.8 mg/dL ± 48.5 mg/dL; p = 0.007). However, the patients who received empagliflozin experienced a significantly greater reduction in mean FBG than patients who received dapagliflozin (p = 0.001). HbA1c was also significantly reduced in both groups (empagliflozin: -2.1% ± 1.1%, p = 0.002; dapagliflozin: -1.4% ± 0.9%; p = 0.004). However, patients who received empagliflozin experienced a significantly greater reduction in HbA1c than patients who received dapagliflozin (p = 0.001). The tolerability profiles of both SGLT-2 agents were quite good, and no major adverse effects were reported in the study groups. Urinary infection occurred more often in patients who received dapagliflozin (9.3%) than in patients who received empagliflozin (4.5%; p = 0.002). Patients in the dapagliflozin group also had a higher incidence of genital infections (7.3%) than those in the empagliflozin group (3.8%; p = 0.001). Conclusion Both empagliflozin and dapagliflozin demonstrated excellent efficacy and safety profiles in our study. These agents should be considered as add-on therapy in patients with type 2 diabetes taking conventional first-line OADs.
- Open Access
- 1 November 2020
- Published by Sheik Zayed Medical College in Journal of Sheikh Zayed Medical College
- Vol. 11 (4) , 1-2
Green Tea and Nigella Sativa- Herbs in Non-Alcoholic Fatty Liver Disease
Non-alcoholic fatty liver disease (NAFLD) is the foremost cause of progressive liver disorder worldwide. It has strong association with obesity 41-61%, metabolic syndrome 30-56%, Type-2 diabetes 18- 28%, dyslipidemia 52-83% and hypertension 15- 46%. These risk factors promote NAFLD as a global health issue especially in western countries with a prevalence rate of about 20-30%. In recent years, the prevalence rate of 15-30% has been found in Asian countries in the general population due to the strong influence of lifestyle modification and urbanization patterns on the associated risk factors. There is an urgent need to reduce the enormous clinical and economic burden of NAFLD globally.1 Lifestyle modification in the form of the diet, weight loss, and physical exercises is advocated as the first line of intervention in NAFLD patients.2 However, there is no effective FDA drug treatment for NAFLD patients so far. Due to the presence of associated comorbidities in NAFLD patients various drugs such as insulin sensitizers, antioxidants, antidyslipidemic, hepatoprotective (silymarin), and miscellaneous agents like pentoxifylline, orlistat, and incretin-based therapies with varying results have been tried up till now.3 Green Tea is an unfermented product of the leaves and bark of the plant (Camellia sinensis) and is one of the famous drinks all over the world especially in the region of southeast Asia. Green Tea contains thousands of bioactive compounds out of which one-third is contributed by polyphenols which are mostly flavonoids.4 Catechins are one of the main flavonoids in green tea has recently attracted attention for their use in various diseases due to their antiaging, anti-cancer, anti-parkinsonism, anti-stroke, anti-diabetic, anti-caries and anti-bacterial, anti-diarrheal, anti-fibrotic, anti-inflammatory, anti-oxidative, and anti-atherosclerotic properties. Green tea has a strong potential to reverse all those suspected mechanisms that have been suspected in the pathogenesis of NAFLD in various clinical and experimental studies. Green tea decrease hepatic steatosis by reducing hepatic insulin resistance, which is a key mechanism in its pathogenesis.5 Green tea has a strong potential to boost the immune system, reduces the formation of reactive oxygen species (ROS), increases the activity of pro-oxidant enzymes such as glutathione peroxidase and superoxide dismutase through its antioxidant properties and finally, green tea reduces various inflammatory chemokines and cytokines as inflammation and oxidative stress is the pathognomonic features in NAFLD related complication. In addition green tea has a beneficial effect on all NAFLD-associated medical conditions such as obesity, metabolic syndrome, hypertension, and dyslipidemia in various clinical studies.6 Nigella sativa a natural remedy for a variety of medical ailments has been used for centuries due to its historical and religious background. Although it exists in several forms but according to our Prophet (PBUH) saying its seeds are the remedy for all the diseases except death. It is also called black seeds, black cumin, black caraway, fennel flower, nutmeg flower, kalonji and used for centuries as home remedies and culinary proposes in South Asia.5 It is a miracle herb and has a potential for use in a variety of medical clinical condition such as diabetic mellitus, dyslipidemia, asthma, hypertension, diarrhea, peptic ulcer, rheumatoid arthritis, osteoporosis. In addition, it has anti-inflammatory, anti-oxidant, anti-fibrotic, antipyretic, analgesic, antibacterial, anti-fungal, anti-parasitic, anti-viral, anti-tumor, and immunomodulatory properties. Nigella sativa has beneficial effects on all those risk factors which are associated with NAFLD in various clinical studies such as improvement in metabolic syndrome, blood pressure, and weight gain, and lipid profiles.6 Moreover, it has also having anti-inflammatory and anti-oxidant properties, because inflammation and oxidative stress plays an important role in the progression as well as complication of NAFLD.7 "This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited".
- 1 November 2020
- Published by Sheik Zayed Medical College in Journal of Sheikh Zayed Medical College
- Vol. 11 (4) , 1-2
Open AccessGreen Tea and Nigella Sativa- Herbs in Non-Alcoholic Fatty Liver Disease
Non-alcoholic fatty liver disease (NAFLD) is the foremost cause of progressive liver disorder worldwide. It has strong association with obesity 41-61%, metabolic syndrome 30-56%, Type-2 diabetes 18- 28%, dyslipidemia 52-83% and hypertension 15- 46%. These risk factors promote NAFLD as a global health issue especially in western countries with a prevalence rate of about 20-30%. In recent years, the prevalence rate of 15-30% has been found in Asian countries in the general population due to the strong influence of lifestyle modification and urbanization patterns on the associated risk factors. There is an urgent need to reduce the enormous clinical and economic burden of NAFLD globally.1 Lifestyle modification in the form of the diet, weight loss, and physical exercises is advocated as the first line of intervention in NAFLD patients.2 However, there is no effective FDA drug treatment for NAFLD patients so far. Due to the presence of associated comorbidities in NAFLD patients various drugs such as insulin sensitizers, antioxidants, antidyslipidemic, hepatoprotective (silymarin), and miscellaneous agents like pentoxifylline, orlistat, and incretin-based therapies with varying results have been tried up till now.3 Green Tea is an unfermented product of the leaves and bark of the plant (Camellia sinensis) and is one of the famous drinks all over the world especially in the region of southeast Asia. Green Tea contains thousands of bioactive compounds out of which one-third is contributed by polyphenols which are mostly flavonoids.4 Catechins are one of the main flavonoids in green tea has recently attracted attention for their use in various diseases due to their antiaging, anti-cancer, anti-parkinsonism, anti-stroke, anti-diabetic, anti-caries and anti-bacterial, anti-diarrheal, anti-fibrotic, anti-inflammatory, anti-oxidative, and anti-atherosclerotic properties. Green tea has a strong potential to reverse all those suspected mechanisms that have been suspected in the pathogenesis of NAFLD in various clinical and experimental studies. Green tea decrease hepatic steatosis by reducing hepatic insulin resistance, which is a key mechanism in its pathogenesis.5 Green tea has a strong potential to boost the immune system, reduces the formation of reactive oxygen species (ROS), increases the activity of pro-oxidant enzymes such as glutathione peroxidase and superoxide dismutase through its antioxidant properties and finally, green tea reduces various inflammatory chemokines and cytokines as inflammation and oxidative stress is the pathognomonic features in NAFLD related complication. In addition green tea has a beneficial effect on all NAFLD-associated medical conditions such as obesity, metabolic syndrome, hypertension, and dyslipidemia in various clinical studies.6 Nigella sativa a natural remedy for a variety of medical ailments has been used for centuries due to its historical and religious background. Although it exists in several forms but according to our Prophet (PBUH) saying its seeds are the remedy for all the diseases except death. It is also called black seeds, black cumin, black caraway, fennel flower, nutmeg flower, kalonji and used for centuries as home remedies and culinary proposes in South Asia.5 It is a miracle herb and has a potential for use in a variety of medical clinical condition such as diabetic mellitus, dyslipidemia, asthma, hypertension, diarrhea, peptic ulcer, rheumatoid arthritis, osteoporosis. In addition, it has anti-inflammatory, anti-oxidant, anti-fibrotic, antipyretic, analgesic, antibacterial, anti-fungal, anti-parasitic, anti-viral, anti-tumor, and immunomodulatory properties. Nigella sativa has beneficial effects on all those risk factors which are associated with NAFLD in various clinical studies such as improvement in metabolic syndrome, blood pressure, and weight gain, and lipid profiles.6 Moreover, it has also having anti-inflammatory and anti-oxidant properties, because inflammation and oxidative stress plays an important role in the progression as well as complication of NAFLD.7 "This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited".
- 1 May 2019
- Vol. 32 (3) , 1343-1348
Effect of vitamin D supplementation on various parameters in non-alcoholic fatty liver disease patients
There are still no FDA approved drugs for NAFLD so far. Vitamin D may be a good therapeutic option for NAFLD patients due to its insulin sensitizing and anti-inflammatory properties. The purpose is to investigate the effect of oral vitamin D supplementation on various parameters in NAFLD patients. In this double blind randomized placebo controlled trial, 109 patients of NAFLD diagnosed by abdominal ultrasound and liver enzymes were divided into two groups for treatment with oral capsule of vitamin D3 50,000 IU and capsule placebo weekly for a period of 12 weeks. Anthropometric, chemical, metabolic and inflammatory parameters were assessed pre and post treatment by using SPSS 16. After 12 weeks oral treatment with vitamin D, its level increased significantly in vitamin D group from 12.5 +/- 4.2 to 24.5 +/- 3.8 ng/ml p=0.003 vs placebo group. This rise was further accompanied by decrease in HOMA-IR (4.56 +/- 1.6 to 3.26 +/- 1.8 p=0.003) liver enzymes (i.e. ALT: 72.+/- 17.6 to 54.5 +/- 14.5 IU/L p=0.04; AST: 68 +/- 14.5 to 46.+/- 10.5 p=0.002) serum CRP 3.25 +/- 0.68 to 2.28 +/- 0.44 mg/L p=0.06 and increase in serum adiponectin 8.56 +/- 1.12 to 10.44 +/- 2.35 mg/L p=0.03 as compared to placebo group. However non significant changes were observed in both groups in terms of body weight, BMI, and serum lipid profiles. Vitamin D supplementation not only improved its own status but also caused a significant amelioration in metabolic, chemical and inflammatory parameters in NAFLD patients. So it should be consider as an adjunctive therapy in NAFLD patients.
- 1 May 2019
- Vol. 32 (3) , 1343-1348
Effect of vitamin D supplementation on various parameters in non-alcoholic fatty liver disease patients
There are still no FDA approved drugs for NAFLD so far. Vitamin D may be a good therapeutic option for NAFLD patients due to its insulin sensitizing and anti-inflammatory properties. The purpose is to investigate the effect of oral vitamin D supplementation on various parameters in NAFLD patients. In this double blind randomized placebo controlled trial, 109 patients of NAFLD diagnosed by abdominal ultrasound and liver enzymes were divided into two groups for treatment with oral capsule of vitamin D3 50,000 IU and capsule placebo weekly for a period of 12 weeks. Anthropometric, chemical, metabolic and inflammatory parameters were assessed pre and post treatment by using SPSS 16. After 12 weeks oral treatment with vitamin D, its level increased significantly in vitamin D group from 12.5 +/- 4.2 to 24.5 +/- 3.8 ng/ml p=0.003 vs placebo group. This rise was further accompanied by decrease in HOMA-IR (4.56 +/- 1.6 to 3.26 +/- 1.8 p=0.003) liver enzymes (i.e. ALT: 72.+/- 17.6 to 54.5 +/- 14.5 IU/L p=0.04; AST: 68 +/- 14.5 to 46.+/- 10.5 p=0.002) serum CRP 3.25 +/- 0.68 to 2.28 +/- 0.44 mg/L p=0.06 and increase in serum adiponectin 8.56 +/- 1.12 to 10.44 +/- 2.35 mg/L p=0.03 as compared to placebo group. However non significant changes were observed in both groups in terms of body weight, BMI, and serum lipid profiles. Vitamin D supplementation not only improved its own status but also caused a significant amelioration in metabolic, chemical and inflammatory parameters in NAFLD patients. So it should be consider as an adjunctive therapy in NAFLD patients.